Inpart Logo
Campaign Preview

Seeking Research in B cell and Plasma Cell Depletion Programs

Closed

Opportunity types being sought:

Technologies
Academic Profiles
Centres of Excellence
Research Projects
Spinout Companies
Header

CSL is interested in research in the broader area of autoimmunity, with a focus on autoantibody, complement and T cell‑mediated diseases. The focus of this search is on removing or downmodulating the autoimmune component causing disease, while simultaneously preserving protective immunity.

Approaches of Particular Interest

  • Antibody‑based Therapeutics
  • Bi‑specific (T-cell engaging) Approaches
  • Antibody‑Drug Conjugates 
  • Biologics
  • Tolerance Induction
  • Cell and Gene Therapies

Development Stage

  • Opportunities at the levels of basic through to late pre‑clinical research 
  • Targets validated by patient data, biomarker identification and/or animal models would be advantageous
  • Multi-omics data welcomed

Submission Information

One‑page research summaries are encouraged, plus any relevant non‑confidential supporting documents 

Out of Scope

  • Research focused on Rheumatoid Arthritis (RA) or Oncology are not of interest. However, Oncology or RA‑related research will be considered if there are broader applications in autoimmunity.
  • Small molecule therapeutic approaches are not within scope. RNA/nucleotide therapeutic approaches will be considered, but are not a priority.

Opportunity for Collaboration

CSL is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case by case basis. Example outcomes include licensing assets, or research collaborations (such as the creation of a joint steering committee consisting of academics and industry experts in the field at CSL).